These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 8371371

  • 1. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.
    Moore MJ, Iscoe N, Tannock IF.
    J Urol; 1993 Oct; 150(4):1131-4. PubMed ID: 8371371
    [Abstract] [Full Text] [Related]

  • 2. Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors.
    Sternberg CN, de Mulder PH, van Oosterom AT, Fossa SD, Giannarelli D, Soedirman JR.
    Ann Oncol; 1993 May; 4(5):403-7. PubMed ID: 8353075
    [Abstract] [Full Text] [Related]

  • 3. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ, Elson P, Dreicer R, Hahn R, Nichols CR, Williams R, Einhorn LH.
    J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
    [Abstract] [Full Text] [Related]

  • 4. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsch J, Kelly WK, Scher HI, Bajorin DF.
    J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
    von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF.
    J Clin Oncol; 2000 Sep; 18(17):3068-77. PubMed ID: 11001674
    [Abstract] [Full Text] [Related]

  • 11. Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity.
    Conti JA, Scher HI.
    Cancer; 1992 Dec 01; 70(11):2699-702. PubMed ID: 1384952
    [Abstract] [Full Text] [Related]

  • 12. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer.
    Miyanaga N, Akaza H, Shimazui T, Ohtani M, Koiso K.
    Cancer Chemother Pharmacol; 1994 Dec 01; 35 Suppl():S5-8. PubMed ID: 7527735
    [Abstract] [Full Text] [Related]

  • 13. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
    Bellmunt J, Ribas A, Eres N, Albanell J, Almanza C, Bermejo B, Solé LA, Baselga J.
    Cancer; 1997 Nov 15; 80(10):1966-72. PubMed ID: 9366300
    [Abstract] [Full Text] [Related]

  • 14. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA.
    J Clin Oncol; 1992 Jul 15; 10(7):1066-73. PubMed ID: 1607913
    [Abstract] [Full Text] [Related]

  • 15. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
    Nakanishi S, Matsuzaki M, Morikawa H, Nakano M, Komatsu H.
    Hinyokika Kiyo; 2004 Oct 15; 50(10):667-71. PubMed ID: 15575216
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.
    Seidman AD, Scher HI, Gabrilove JL, Bajorin DF, Motzer RJ, O'Dell M, Curley T, Dershaw DD, Quinlivan S, Tao Y.
    J Clin Oncol; 1993 Mar 15; 11(3):408-14. PubMed ID: 7680373
    [Abstract] [Full Text] [Related]

  • 19. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management].
    Noguchi S, Kubota Y, Shuin T, Masuda M, Misaki H, Yao M, Kondoh K, Sakuramoto T, Hosaka M.
    Hinyokika Kiyo; 1994 Aug 15; 40(8):677-82. PubMed ID: 7942364
    [Abstract] [Full Text] [Related]

  • 20. Effect of recombinant human granulocyte colony-stimulating factor in patients receiving chemotherapy for urogenital cancer. Urological rhG-CSF Study Group.
    Aso Y, Akaza H.
    J Urol; 1992 Apr 15; 147(4):1060-4. PubMed ID: 1372661
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.